BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25879784)

  • 1. Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.
    Beca F; Pereira M; Cameselle-Teijeiro JF; Martins D; Schmitt F
    BMC Cancer; 2015 Apr; 15():285. PubMed ID: 25879784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
    Wang ZB; Zhao P; Liu M; Li XH
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
    Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
    Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
    Mottolese M; Orlandi G; Sperduti I; Merola R; Buglioni S; Di Benedetto A; Pinnarò P; Perracchio L; Venturo I; Cognetti F; Cianciulli A
    Am J Surg Pathol; 2007 Feb; 31(2):247-54. PubMed ID: 17255770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
    Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
    Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
    Reis-Filho JS; Savage K; Lambros MB; James M; Steele D; Jones RL; Dowsett M
    Mod Pathol; 2006 Jul; 19(7):999-1009. PubMed ID: 16648863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
    Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
    Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p-mTOR expression is associated with better prognosis in luminal breast carcinoma.
    Beca F; Andre R; Martins DS; Bilhim T; Martins D; Schmitt F
    J Clin Pathol; 2014 Nov; 67(11):961-7. PubMed ID: 25053543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
    Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
    Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
    Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
    Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort.
    Liu J; Yu W; Gao F; Qi S; Du J; Ma X; Zhang Y; Zheng J; Su J
    Diagn Pathol; 2021 Jul; 16(1):60. PubMed ID: 34225728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
    Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
    Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
    Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of miR-556-5p promoted prostate cancer cell proliferation by suppressing PPP2R2A expression.
    Zhao W; Cao L; Zeng S; Qin H; Men T
    Biomed Pharmacother; 2015 Oct; 75():142-7. PubMed ID: 26297546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.